Shi, Y., Cui, D., Xia, L., Shi, D., Jin, G., Wang, S., . . . Zhai, B. (2024). Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas. Signal Transduction and Targeted Therapy, 9(1), 1. https://doi.org/10.1038/s41392-024-02085-8
Chicago-referens (17:e uppl.)Shi, Yaoping, et al. "Efficacy and Safety of Lenvatinib Plus Gefitinib in Lenvatinib-resistant Hepatocellular Carcinomas." Signal Transduction and Targeted Therapy 9, no. 1 (2024): 1. https://doi.org/10.1038/s41392-024-02085-8.
MLA-referens (9:e uppl.)Shi, Yaoping, et al. "Efficacy and Safety of Lenvatinib Plus Gefitinib in Lenvatinib-resistant Hepatocellular Carcinomas." Signal Transduction and Targeted Therapy, vol. 9, no. 1, 2024, p. 1, https://doi.org/10.1038/s41392-024-02085-8.
